Clinical Research Directory

Inclusion Criteria: * Normal fasting plasma glucose and glycated hemoglobin (HbA1c) \<42 mmol/mol * Body mass index (BMI) between 18.5 and 25 kg/m2 * Hemoglobin \>8.3 mmol/l * Participants must consume a ordinary mixed diet and not follow restrictive or specialized dietary regimens * Age between 20 and 40 years * Oral and written informed consent Exclusion Criteria: * Diabetes * Known gastrointestinal disease, major or recent abdominal surgery * First degree relatives with inflammatory bowel disease * History of BMI \> 30. * Current or history of psychiatric eating disorder * Regular use of nicotine products in any form * Regular alcohol intake above 18 units per week * Fasting plasma triacylglycerol indicating dyslipidemia (≥2 mmol/l) Nephropathy (estimated glomerular filtration rate (eGFR) \<60 ml/min and/or albuminuria with an albumin to creatinine ratio of \>30 μg/mg) * Known liver disease and/or alanine aminotransferase (ALT) \>2 × upper reference limits * Signs of liver fibrosis and/or steatosis evaluated by FibroScan (CAP value \>238 dB/m and/or kPa \>5.0) and/or FIB-4 score (\>1.45) * Regular use of prescription medication or treatment with systemic antibiotics less than three weeks before the screening visit. * Use of over-the-counter medication or any dietary supplements known to alter gastrointestinal function, including probiotics, for the period of the study and three weeks prior to screening * More than two weekly strength and/or aerobic training sessions on a regular basis * Physical or mental conditions incompatible with magnetic resonance scanning modalities, including implanted metal objects. * Not willing to agree to use effective contraception during and for 90 days after end of the diet intervention. Acceptable contraception includes condom use and/or ensuring that the female partner(s) uses highly effective contraception. * Any condition that the investigator feels would interfere with study completion